9/13/22, 6:58 PM ICH Official web site : ICH

Home \ ICH Guidelines \ Quality Guidelines

Quality Guidelines
Harmonisation achievements in the Quality area include pivotal milestones such as the conduct of stability studies, defining relevant
thresholds for impurities testing and a more flexible approach to pharmaceutical quality based on Good Manufacturing Practice (GMP)
risk management.

Q1A - Q1F 
Stability

Q1A(R2) Stability Testing of New Drug Substances and Products



Q1B Stability Testing : Photostability Testing of New Drug Substances and Products


Q1C Stability Testing for New Dosage Forms



Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and
Q1D


Products

Q1E Evaluation of Stability Data



Q1F Stability Data Package for Registration Applications in Climatic Zones III and IV


Q1/Q5C informal WG Targeted Revisions of the ICH Stability Guideline Series



Q2 Analytical 
Validation

Q2(R1) Validation of Analytical Procedures: Text and Methodology



Q2(R2)/Q14 EWG Analytical Procedure Development and Revision of Q2 (R1) Analytical Validation


Q3A - Q3E 
Impurities

Q3A(R2) Impurities in New Drug Substances



Q3B(R2) Impurities in New Drug Products



Q3C(R8) Guideline for Residual Solvents



Q3C(R9) Maintenance EWG Maintenance of the Guideline for Residual Solvents



Q3D(R2) Guideline for Elemental Impurities



Q3D(R3) Maintenance EWG Maintenance of the Guideline for Elemental Impurities



https://www.ich.org/page/quality-guidelines 1/4
9/13/22, 6:58 PM ICH Official web site : ICH

Q3D training Implementation of Guideline for Elemental Impurities


 Q3E EWG
Impurity: Assessment and Control of Extractables and Leachables for
Pharmaceuticals and Biologics

Q4A - Q4B 
Pharmacopoeias

Q4A Pharmacopoeial Harmonisation



Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH

Q4B


Regions

Q4B Annex 1(R1) Residue on Ignition/Sulphated Ash General Chapter



Q4B Annex 2(R1) Test for Extractable Volume of Parenteral Preparations General Chapter


Q4B Annex 3(R1) Test for Particulate Contamination: Sub-Visible Particles General Chapter


Q4B Annex Microbiological Examination of Non-Sterile Products: Microbial Enumeration



4A(R1) Tests General Chapter

Q4B Annex Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-


4B(R1) Organisms General Chapter

Microbiological Examination of Non-Sterile Products: Acceptance Criteria for

Q4B Annex


Pharmaceutical Preparations and Substances for Pharmaceutical Use General

4C(R1)
Chapter

Q4B Annex 5(R1) Disintegration Test General Chapter



Q4B Annex 6 Uniformity of Dosage Units General Chapter



Q4B Annex 7(R2) Dissolution Test General Chapter



Q4B Annex 8(R1) Sterility Test General Chapter



Q4B Annex 9(R1) Tablet Friability General Chapter



Q4B Annex 10(R1) Polyacrylamide Gel Electrophoresis General Chapter



Q4B Annex 11 Capillary Electrophoresis General Chapter



Q4B Annex 12 Analytical Sieving General Chapter



Q4B Annex 13 Bulk Density and Tapped Density of Powders General Chapter


Q4B Annex 14 Bacterial Endotoxins Test General Chapter



Q4B FAQs Frequently Asked Question



Q5A - Q5E Quality of Biotechnological 

Products
Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human
Q5A(R1)


or Animal Origin

Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human


EWG or Animal Origin

https://www.ich.org/page/quality-guidelines 2/4
9/13/22, 6:58 PM ICH Official web site : ICH

Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived
Q5B

Protein Products
Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological
Q5C

Products
Derivation and Characterisation of Cell Substrates Used for Production of
Q5D


Biotechnological/Biological Products
Comparability of Biotechnological/Biological Products Subject to Changes in their
Q5E


Manufacturing Process

Q6A- Q6B 
Specifications
Specifications : Test Procedures and Acceptance Criteria for New Drug Substances
Q6A


and New Drug Products: Chemical Substances

Specifications : Test Procedures and Acceptance Criteria for
Q6B


Biotechnological/Biological Products

Q7 Good Manufacturing 
Practice

Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients



Questions and Answers: Good Manufacturing Practice Guide for Active

Q7 Q&As


Pharmaceutical Ingredients

Q8 Pharmaceutical 
Development

Q8(R2) Pharmaceutical Development



Q8/9/10 Q&As (R4) Q8/Q9/Q10 - Implementation



Q9 Quality Risk 
Management

Q9 Quality Risk Management



Q9(R1) EWG Quality Risk Management



Q8/9/10 Q&As (R4) Q8/Q9/Q10 - Implementation



Q10 Pharmaceutical Quality 

System

Q10 Pharmaceutical Quality System



Q8/9/10 Q&As (R4) Q8/Q9/Q10 - Implementation



Q11 Development and Manufacture of Drug 

Substances
Development and Manufacture of Drug Substances (Chemical Entities and
Q11


Biotechnological/Biological Entities)
Questions & Answers: Selection and Justification of Starting Materials for the


Q11 Q&As f f b
https://www.ich.org/page/quality-guidelines 3/4
9/13/22, 6:58 PM ICH Official web site : ICH
Q11 Q&As Manufacture of Drug Substances

Q12 Lifecycle 
Management

Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle

Q12


Management
Training on Regulatory and Technical Considerations for Pharmaceutical Product
Q12 IWG


Lifecycle Management

Q13 Continuous Manufacturing of Drug Substances and Drug 

Products

Q13 EWG Continuous Manufacturing of Drug Substances and Drug Products



Q14 Analytical Procedure 

Development

Q2(R2)/Q14 EWG Analytical Procedure Development and Revision of Q2 (R1) Analytical Validation


https://www.ich.org/page/quality-guidelines 4/4